FIMI

Pinkfong's Baby Shark Bags its First Gold Certification in France

Retrieved on: 
Tuesday, February 6, 2024

SEOUL, South Korea, Feb. 6, 2024 /PRNewswire/ -- The Pinkfong Company, the global entertainment company behind Baby Shark, today announced that its Baby Shark single received its first official Gold certification from France's National Syndicate of Phonographic Publishing (SNEP). With 15 million cumulative streams in France, Pinkfong's "Baby Shark" made history as the first Korean animation to earn gold certification in France.

Key Points: 
  • With 15 million cumulative streams in France, Pinkfong's "Baby Shark" made history as the first Korean animation to earn gold certification in France.
  • Baby Shark has captured the hearts of listeners in Europe, earning additional certifications across Europe with its iconic song.
  • According to The Official Charts in December 2022, Pinkfong's Baby Shark placed 8th on the UK's Official Top 200 most-streamed song chart.
  • The world-renowned "Baby Shark" song became a breakout sensation, recording a 20-week streak on the Billboard Hot 100 and receiving RIAA Diamond certification (11x Platinum).

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Retrieved on: 
Monday, November 13, 2023

“Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.

Key Points: 
  • “Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.
  • Financial Highlights for the Three Months Ended September 30, 2023
    Total revenues were $37.9 million in the third quarter of 2023, an 18% increase from the $32.2 million recorded in the third quarter of 2022.
  • S&M costs, for the third quarter of 2023 and 2022, included $0.4 million of depreciation expenses of intangible assets generated through the IgG products acquisition.
  • Kamada continues to expect to generate fiscal year 2023 total revenues in the range of $138 million to $146 million.

Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

Retrieved on: 
Wednesday, August 30, 2023

Under the terms of the Private Placement, Kamada will be issuing an aggregate of approximately 12.6 million ordinary shares to FIMI at a price of $4.75 per share (which represented the average closing price of the Company’s shares on NASDAQ during the 20 trading days prior to the date of execution of the Private Placement).

Key Points: 
  • Under the terms of the Private Placement, Kamada will be issuing an aggregate of approximately 12.6 million ordinary shares to FIMI at a price of $4.75 per share (which represented the average closing price of the Company’s shares on NASDAQ during the 20 trading days prior to the date of execution of the Private Placement).
  • Upon closing of the Private Placement, expected during the first week of September, FIMI will beneficially own approximately 38% of Kamada’s outstanding ordinary shares and will become a controlling shareholder of the Company, within the meaning of the Israeli Companies Law, 1999 (the "Companies Law").
  • “We are grateful for the support of FIMI and our shareholders in approving the $60 million private placement,” said Amir London, Kamada’s Chief Executive Officer.
  • Any offering of the ordinary shares under the resale registration statement will only be by means of a prospectus.

Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

Retrieved on: 
Wednesday, August 16, 2023

“Our strong start to 2023 continued in the second quarter, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.

Key Points: 
  • “Our strong start to 2023 continued in the second quarter, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.
  • Financial Highlights for the Three Months Ended June 30, 2023
    Total revenues were $37.4 million in the second quarter of 2023, a 59% increase from the $23.6 million recorded in the second quarter of 2022.
  • Gross profit and gross margins were $14.4 million and 39%, respectively, in the second quarter of 2023, compared to $7.2 million and 31%, respectively, reported in the second quarter of 2022.
  • Adjusted EBITDA, as detailed in the tables below, was $6.0 million in the second quarter of 2023, as compared to $1.3 million in the second quarter of 2022.

Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

Retrieved on: 
Wednesday, May 24, 2023

“We are off to an excellent start to 2023, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.

Key Points: 
  • “We are off to an excellent start to 2023, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.
  • “As such, we are reiterating our full-year 2023 revenue guidance of $138 million to $146 million and EBITDA guidance of $22 million to $26 million, which would represent profitability growth of over 30% as compared to 2022.
  • During the first quarter of 2023, Kamada conducted a planned workforce downsizing at its Israeli plant, optimizing staff level to its capacity needs.
  • Kamada continues to expect to generate fiscal year 2023 total revenues in the range of $138 million to $146 million.

Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds

Retrieved on: 
Wednesday, May 24, 2023

Proceeds from the Private Placement are expected to be used to support the Company’s growth plans and execution of strategic business development opportunities.

Key Points: 
  • Proceeds from the Private Placement are expected to be used to support the Company’s growth plans and execution of strategic business development opportunities.
  • “This $60 million private placement is indicative of the confidence FIMI has in Kamada’s significant growth potential,” said Amir London, Kamada’s Chief Executive Officer.
  • The special committee received fairness opinions from financial advisors regarding the terms of the Private Placement and retained its own legal counsel.
  • The securities offered under the Private Placement have not been registered under the Securities Act of 1933, as amended.

Senstar Technologies Announces Appointment of Amit Ben-Zvi to Board of Directors

Retrieved on: 
Monday, April 24, 2023

RAMAT GAN, Israel, April 24, 2023 /PRNewswire/ -- Senstar Technologies (NASDAQ: SNT), a leading provider of sensing and information management solutions for the protection of critical infrastructure, announced today the appointment of Amit Ben-Zvi to the Senstar Technologies Board of Directors, effective April 21, 2023.

Key Points: 
  • RAMAT GAN, Israel, April 24, 2023 /PRNewswire/ -- Senstar Technologies (NASDAQ: SNT), a leading provider of sensing and information management solutions for the protection of critical infrastructure, announced today the appointment of Amit Ben-Zvi to the Senstar Technologies Board of Directors, effective April 21, 2023.
  • Mr. Ben-Zvi has served as a Senior Partner of FIMI Opportunity Fund since 2012.
  • From 1998 to 2012, Mr. Ben-Zvi served in senior executive positions: COO at Top Image Systems (NASDAQ: TASE), CEO at ISYS Operational Management Systems, CEO at Wizcom Technologies (FRANKFURT), GM Europe & Japan at Magic Software Enterprise (NASDAQ: TASE) and CEO at Hermes Logistics Technologies.
  • degree (Bachelor of Law), Cum Laude, from Tel Aviv University.

BrainsWay Announces Appointment of Ami Boehm as New Chairman

Retrieved on: 
Monday, February 13, 2023

and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ami Boehm, as Chairman of the Board.

Key Points: 
  • and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ami Boehm, as Chairman of the Board.
  • David Zacut, M.D., co-founder of BrainsWay, who has held the role of Chairman since the Company’s inception, will now serve as a Director on the Board.
  • “After 19 intensive years, and with BrainsWay well-positioned for its next phase of growth, now is the right time for me to take a step back.
  • Mr. Boehm received a Master’s of Business Administration from Northwestern University and Tel-Aviv University, a Bachelor of Law from Tel-Aviv University, and a Bachelor of Economics from Tel-Aviv University.

Highlights - 08-12-2022 14:30 Exchange of views with HR/VP Josep Borrell - Special Committee on foreign interference in all democratic processes in the European Union, including disinformation (INGE 2)

Retrieved on: 
Tuesday, November 29, 2022

08-12-2022 14:30 Exchange of views with HR/VP Josep Borrell

Key Points: 
  • 08-12-2022 14:30 Exchange of views with HR/VP Josep Borrell
    29-11-2022 - 16:26
    On 8 December from 14.30 to 15.45, ING2 Members will welcome Vice-President of the European Commission/High Representative of the Union of the Union for Foreign Affairs and Security Policy Mr Josep Borrell, to the special committee.
  • As a follow-up to the recommendations from the INGE-report, ING2 Members will discuss, together with Members from AFET and SEDE, what steps have been taken since the adoption of the INGE report in March 2022.
  • Members will question the HR/VP on the progress of some of the latest initiatives taken by the EU touching upon INGE-related topics, such as measures to tackle information manipulation in the context of the Russia's war of aggression against Ukraine, efficiency of sanctions targeting RT/Sputnik, the FIMI toolbox development, and preparedness for the 2024 European elections.

Rafa Receives FDA Approval For Life-saving Midazolam Autoinjector

Retrieved on: 
Tuesday, August 30, 2022

JERUSALEM, Aug. 30, 2022 /PRNewswire/ -- Rafa Laboratories LTD. ("Rafa") is pleased to announce the U.S. Food and Drug Administration has approved its "first in market" 10 mg midazolam autoinjector for the treatment of status epilepticus in adults.

Key Points: 
  • The Midazolam 10 mg autoinjector is indicated for the treatment of status epilepticus, or prolonged seizures, in adults.
  • According to the U.S. JPEO-CBRND, the autoinjector improves upon and will replace the currently fielded convulsant antidote for nerve agent (CANA) diazepam autoinjector.
  • FDA approval was obtained following an expedited review, a testament to the importance and urgent need of the product, with NDA submission and final approval achieved in less than five months through prioritized engagement between the U.S. DOD and the FDA.
  • Amir Levin, CEO of Rafa, stated:"We are proud of the FDA approval for this life saving product.